Vitamin B3 Fights Aggressive Brain Cancer

High-dose niacin, a common vitamin B3 supplement, is showing potential in combating glioblastoma, a highly aggressive brain cancer. Early preclinical studies suggest niacin can enhance immune activity, aiding in disease control when combined with standard therapies like surgery, radiation, and chemotherapy. In a trial involving 24 glioblastoma patients, 82% exhibited no disease progression after six months of niacin supplementation, a significant improvement over the typical 54%.

Niacin was observed to restore function in compromised immune cells, improving their capacity to target and destroy tumor cells. This effect is crucial as glioblastoma is known to suppress the immune system. The lead author described the treatment as rejuvenating immune cells to effectively attack the cancer. Researchers plan to enroll an additional 24 patients by late 2026 or early 2027 for further safety and immune response assessments.

Despite these encouraging findings, researchers emphasize caution due to the study's small sample size and lack of a randomized control group. Larger, controlled trials are necessary to confirm these results. While niacin may offer a small impact, it is not considered a cure, and high doses can pose health risks, requiring medical supervision.